COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

Demographic and Outcome Characteristics of Children Hospitalized with Acute COVID-19 versus Multisystem Inflammatory Syndrome in Children in Canada

Daniel S. Farrar MPH¹, Charlotte Moore Hepburn MD^{2,3}, Olivier Drouin MDCM^{5,6}, Tala El Tal MD⁷, Marie-Paule Morin MD⁸, Roberta A. Berard MD⁴, Melanie King BA⁹, Melanie Laffin Thibodeau BCom⁹, Elie Haddad MD⁸, Rosie Scuccimarri MD¹⁰, Rae S. M. Yeung MD^{7,11,12}, Fatima Kakkar MD^{13*}, Shaun K. Morris MD^{1,14–16*} for the Canadian Paediatric Surveillance Program COVID-19 Study Team

¹Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada; ²Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Canada; ³Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada; ⁴Division of Rheumatology, Department of Pediatrics, Children's Hospital at London Health Sciences Centre, London, Canada; ⁵Division of General Pediatrics, Department of Pediatrics, CHU Sainte-Justine, Montreal, Canada; ⁶Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, Montréal, Canada; ⁷Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Canada; ⁸Division of Paediatric Rheumatology-Immunology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Canada; ⁹Canadian Paediatric Surveillance Program, Canadian Paediatric Society, Ottawa, Canada; ¹⁰Division of Pediatric Rheumatology, Montreal Children's Hospital and McGill University Health Centre, Montreal, Canada; ¹¹Cell Biology Program, The Hospital for Sick Children, Toronto, Canada; ¹²Department of Immunology and Institute of Medical Science, University of Toronto, Toronto, Canada; ¹³Division of Infectious Diseases, CHU Sainte-Justine, Montreal, Canada; ¹⁴Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Canada; ¹⁶Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Canada; * indicates co-senior authors.

Corresponding authors:

Fatima Kakkar Division of Infectious Diseases, Centre Hospitalier Universitaire Sainte-Justine 3175 Chemin Cote Sainte-Catherine, Montreal, QC, H3T 1C5, Canada <u>fatima.kakkar@umontreal.ca</u>

Shaun K. Morris Division of Infectious Diseases, The Hospital for Sick Children 555 University Ave, Toronto, ON, M5G 1X8, Canada <u>shaun.morris@sickkids.ca</u>

Key words: COVID-19, multisystem inflammatory syndrome in children, hospitalizations, resource use, intensive care

Abbreviations: Adjusted risk difference (aRD); Canadian Paediatric Surveillance Program (CPSP); confidence interval (CI); coronavirus disease 2019 (COVID-19); interquartile range (IQR); multisystem inflammatory syndrome in children (MIS-C); Public Health Agency of Canada (PHAC); pediatric intensive care unit (PICU); Severe acute respiratory disease coronavirus 2 (SARS-CoV-2)

Funders: Financial support for the Canadian Paediatric Surveillance Program was received from the Public Health Agency of Canada.

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

ABSTRACT

Direct comparisons of pediatric hospitalizations for acute COVID-19 and multisystem inflammatory syndrome in children (MIS-C) can inform health system planning. While there were more hospitalizations and deaths from acute COVID-19 amongst Canadian children between March 2020–May 2021, MIS-C cases were more severe, requiring more intensive care and vasopressor support.

INTRODUCTION

Along with hospitalization for acute COVID-19, multisystem inflammatory syndrome in children (MIS-C) has emerged as a serious yet infrequent complication of pediatric SARS-CoV-2 infection. To date, few studies have directly compared characteristics and outcomes associated with these two diagnoses.(1,2) Case series describing MIS-C indicate higher proportions of severe disease relative to acute COVID-19, despite much lower incidence of MIS-C in the community compared to SARS-CoV-2 infection.(3,4) Differences in the associated use of hospital resources (e.g. ventilation or hemodynamic support requiring intensive care) between these two disease entities are not well known, and may have implications for future pediatric pandemic planning. We aimed to describe the absolute and relative hospital burden of acute pediatric COVID-19 infection and MIS-C during the first fifteen months of the pandemic in Canada, prior to the emergence of the Omicron variant and approval of SARS-CoV-2 vaccines for use in children.

METHODS

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

We conducted a national prospective study via the Canadian Paediatric Surveillance Program (CPSP) from March 2020–May 2021. The CPSP is a public health surveillance network which includes >2800 paediatricians across Canada, who voluntarily reported incident cases to this study on a weekly basis. Cases of children <18 years old and hospitalized with acute SARS-CoV-2 infection or pediatric inflammatory multisystem syndrome (PIMS) were eligible to be reported. While cases were reported based on a surveillance definition of PIMS, we applied a post-hoc case definition of MIS-C according to the World Health Organization.(5) By definition, all patients with MIS-C had a documented linkage to SARS-CoV-2 (i.e. positive polymerase chain reaction, rapid antigen, or serology test, or a close contact with microbiologically confirmed SARS-CoV-2). For all SARS-CoV-2 hospitalizations, the reporting physician indicated whether the hospitalization was due to acute COVID-19 or if incidental infection was identified upon routine screening; this was confirmed by dual adjudication by the study team to ensure consistency. We therefore compared two mutually exclusive groups for this analysis: children hospitalized with acute COVID-19 versus children hospitalized with MIS-C. Further details regarding the study design are described elsewhere, and surveillance definitions are available at https://cpsp.cps.ca/surveillance/study-etude/covid-19.(6,7) Ethics approval was obtained at Health Canada-PHAC (REB #2020-002P), the Hospital for Sick Children (REB #1000070001), and the Centre Hospitalier Universitaire Sainte-Justine (conducted as a multicenter study in the province of Quebec; IRB #MP-21-2021-2901).

Baseline characteristics and severity outcomes were ascertained for both case definitions using the same case report form. Severity outcomes included requirements for supplemental oxygen (either low-flow oxygen or high-flow nasal cannula), ventilation (either non-invasive, conventional mechanical, or high-frequency oscillatory ventilation), vasopressors, pediatric

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

intensive care unit (PICU) admissions, or death. Characteristics were summarized using medians, interquartile ranges (IQR), frequencies, and percentages. Frequencies between one and four were reported as '<5' while some larger frequencies were presented as ranges to prevent back-calculation, in accordance with CPSP privacy policy. Adjusted risk differences (aRD) were calculated to identify factors associated with each diagnosis, adjusting for age, sex, presence of \geq 1 comorbid conditions, and the timing of hospitalization (defined as five three-month periods from March 2020–May 2021). Differences in continuous variables (i.e. age and PICU length of stay) were assessed using Wilcoxon rank-sum tests. The temporal lag (in weeks) between all Canadian SARS-CoV-2 case counts (ascertained from the Public Health Agency of Canada(8)) and hospitalizations reported to CPSP were assessed using Spearman's rank correlation coefficient. P-values <0.05 were considered statistically significant. Analyses were conducted in Stata v17.0.

RESULTS

Overall, 330 children hospitalized with acute COVID-19 and 208 hospitalized with MIS-C were reported during the surveillance period (Table 1). The median age among acute COVID-19 patients (1.9 years; IQR 0.1–13.3) was significantly younger than those with MIS-C (8.1 years; IQR 4.2–11.6; p<0.001). More children aged <1 year were hospitalized with acute COVID-19 than with MIS-C (aRD 43.4%; 95% CI 37.7–49.1), while more children aged 5–11 years were hospitalized with MIS-C than acute COVID-19 (aRD 38.9%; 95% CI 31.0–46.9). Chronic comorbid conditions were more common amongst acute COVID-19 patients (43.0% vs. 15.9% with MIS-C; aRD 38.0%; 95% CI 31.0–45.1).

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

PICU admission was required for 49.5% of MIS-C hospitalizations versus 18.2% of acute COVID-19 hospitalizations (aRD 20.3; 95% CI 9.9–30.8), though the proportion of children <5 years admitted to PICU was similar (19.7% vs. 15.4%; Table 2). However, the median length of PICU stay was one day greater for acute COVID-19 (4 days; IQR 2–7) than MIS-C (3 days; IQR 2–4; p=0.04). Vasopressor use was more common for MIS-C than acute COVID-19 at all ages (35.6% vs. 2.4%; aRD 23.1%; 95% CI 15.8–30.4). The proportion of all patients requiring supplemental oxygen and mechanical ventilation were similar (24.6% and 10.9% for acute COVID-19 vs. 30.3% and 9.6% for MIS-C, respectively). Five deaths due to acute COVID-19 were reported versus zero due to MIS-C.

Acute pediatric COVID-19 hospitalization trends lagged behind all Canadian SARS-CoV-2 infection waves by one week (Spearman's ρ 0.89), versus a lag of six weeks for MIS-C hospitalizations (Spearman's ρ 0.82; Appendix Figure 1).

DISCUSSION

Understanding the severity and associated in-hospital resource use required to manage acute pediatric COVID-19 and MIS-C is necessary to anticipate acute health system needs, and to make informed decisions regarding preventative measures including SARS-CoV-2 vaccination. Using national surveillance data from March 2020–May 2021, acute COVID-19 resulted in more pediatric hospitalizations and deaths and longer PICU stays, while MIS-C resulted in more PICU admissions and more frequent need for hemodynamic support. In this study, half of hospitalized MIS-C patients required intensive care, consistent with prior studies from the United Kingdom (44%) and United States (64%) during the first year of the pandemic.(9,10) While PICU admissions among MIS-C patients were often initiated due to

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

shock, these patients were likely stabilized rapidly with immune modulation and vasopressor support. This may explain the shorter PICU stays relative to patients with acute COVID-19, who typically require PICU admission due to respiratory distress and/or exacerbation of chronic comorbid conditions (e.g. neurologic or respiratory disease). The higher vasopressor and intensive care requirements for MIS-C, and similar rates of respiratory support requirements, are consistent with U.S. data from Feldstein et al (2021).(1) A small number of acute COVID-19-related deaths were reported versus none due to MIS-C, in part due to complications from chronic comorbid conditions among children with severe COVID-19.(11)

Despite comparable absolute rates of overall in-hospital resource use, there were important age differences in disease severity and the ensuing strategies used to support these patients. Infants (i.e. <1 year old) rarely required hospitalization for MIS-C, presenting with lower rates of shock, coagulopathy, and myocarditis relative to older children.(7,12) Conversely, infants were the most commonly hospitalized age group for acute COVID-19, in part due to the routine practice of admitting febrile infants for investigations and empiric treatment. Meanwhile, the requirement for hemodynamic support among children \geq 5 years with MIS-C (43–49%) likely led to the high proportion of PICU admission among this age group relative to acute COVID-19, in keeping with other published literature.(2)

While our study period ended prior to dominance of the Delta and Omicron lineages, these and future SARS-CoV-2 lineages may affect the relative in-hospital burden of acute COVID-19 infection and MIS-C. Studies from Denmark and Israel have found the incidence of MIS-C during Omicron waves fell to one-tenth that of prior waves, after accounting for vaccination status.(13,14) Declines in the proportion of MIS-C patients admitted to PICU have also been observed (e.g. 49% during Delta waves to 21% during Omicron waves in Israel(14)),

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

though this may also reflect increased physician knowledge of MIS-C and refinement of supportive and treatment strategies. Uptake of pediatric and adolescent SARS-CoV-2 vaccines may also alter the relative in-hospital burden of disease, having shown effectiveness against both severe COVID-19 and MIS-C.(15)

There are several limitations to this study. First, the voluntary nature of CPSP reporting means that not all pediatric hospitalizations in Canada were identified. Moreover, the limited availability of molecular and serologic testing during the early pandemic likely resulted in some cases failing to meet the case definition of MIS-C. Data were also collected prior to emergence of the Delta and Omicron variants, and before implementation of pediatric and adolescent SARS-CoV-2 vaccine programs. PICU admission criteria may have differed by age, centre, and diagnosis. Nevertheless, this study provided a unique opportunity to compare children hospitalized for acute COVID-19 infection and MIS-C using data ascertained with the same surveillance methods, timeframe, and patient population.

Our findings suggest that both acute COVID-19 and MIS-C need to be considered when assessing the overall burden of SARS-CoV-2 in hospitalized children, and have implications for future pandemic planning with respect to hospital resource use. Given the high proportion of children requiring PICU support for MIS-C, in tandem with the limited number of specialized hospital beds, it is clear these resources need to be anticipated for future pandemic waves. Moreover, given the low overall rates of vaccination among children aged <12 years, awareness of disease severity from both acute COVID-19 and MIS-C may inform parents and policymakers in their decision-making regarding pediatric vaccines.

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

CONFLICTS OF INTEREST

CMH is the Director of Children's Mental Health of Ontario, and the Director of Medical Affairs for the Canadian Paediatric Society and Canadian Paediatric Surveillance Program, MPM has received consulting fees from Sobin and Abbvie and payment for expert testimony from the Canadian Medical Protective Association. RAB has received honoraria and participated in advisory boards with SOBI, Roche, Amgen, and AbbVie. EH has participated in advisory board meetings of CSL-Behring and Takeda, data safety monitoring boards of Rocket Pharmaceutical and Jasper Therapeutics, and has patent applications with Immugenia and Immune Biosolutions. RS has received honoraria and served on an advisory board and as a consultant with Novartis, honoraria from Canadian Rheumatology Association, is a board member for Rheumatology for All, and her institution receives funding from Bristol Myers Squibb for a patient registry for which she is PO. FK has received honoraria for presentations given to the Association des Pédiatres du Québec and receives CMV testing kits from Altona Diagnostics. SKM has received honouraria for lectures from GlaxoSmithKline, was a member of ad hoc advisory boards for Pfizer Canada and Sanofi Pasteur, and is an investigator on an investigator led grant from Pfizer. DSF, OD, TET, MK, MLT, and RSMY have no conflicts of interest to report.

FUNDING STATEMENT

The CPSP is governed by an independent Scientific Steering Committee (SSC) comprised of individuals from both CPS and PHAC (the funder). Members of the SSC reviewed and approved the study design. Individuals from PHAC, CPS, and the SSC participated in interpretation of the data. The final report was provided to PHAC for review, though the study team maintained scientific independence and authors were under no obligation to accept or

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

incorporate changes to the manuscript. DSF wrote the first draft of the manuscript, and no funding was received to produce the manuscript.

DATA STATEMENT

De-identified data that underlie the results reported in this article (text, tables, and figure) and that abide by the privacy rules of the Canadian Paediatric Surveillance Program and the Public Health Agency of Canada can be made available to investigators whose secondary data analysis study protocol has been approved by an independent research ethics board.

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

REFERENCES

- Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021 Mar 16;325(11):1074–87.
- Martin B, DeWitt PE, Russell S, Anand A, Bradwell KR, Bremer C, et al. Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative. JAMA Netw Open. 2022 Feb 1;5(2):e2143151.
- 3. Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatric Respiratory Reviews. 2021 Jun;38:51–7.
- 4. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA Netw Open. 2021 Jun 1;4(6):e2116420.
- 5. World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19: Scientific Brief [Internet]. 2020 [cited 2021 May 3]. Available from: https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
- 6. Farrar DS, Drouin O, Moore Hepburn C, Baerg K, Chan K, Cyr C, et al. Risk factors for severe COVID-19 in hospitalized children in Canada: A national prospective study from March 2020-May 2021. Lancet Reg Health Am. 2022 Nov;15:100337.
- El Tal T, Morin MP, Morris SK, Farrar DS, Berard RA, Kakkar F, et al. Epidemiology and role of SARS-CoV-2 Linkage in Paediatric Inflammatory Multisystem Syndrome (PIMS): A Canadian Paediatric Surveillance Program National Prospective Study [Internet]. 2022. Available from: http://medrxiv.org/content/early/2022/05/27/2022.05.27.22275613.abstract
- 8. Public Health Agency of Canada. COVID-19 daily epidemiology update [Internet]. Government of Canada; 2022 Apr. Available from: https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html
- Flood J, Shingleton J, Bennett E, Walker B, Amin-Chowdhury Z, Oligbu G, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): Prospective, national surveillance, United Kingdom and Ireland, 2020. The Lancet Regional Health - Europe. 2021 Apr;3:100075.
- Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1074–80.

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

- 11. McCormick DW, Richardson LC, Young PR, Viens LJ, Gould CV, Kimball A, et al. Deaths in Children and Adolescents Associated With COVID-19 and MIS-C in the United States. Pediatrics. 2021 Nov;148(5):e2021052273.
- 12. Godfred-Cato S, Tsang CA, Giovanni J, Abrams J, Oster ME, Lee EH, et al. Multisystem Inflammatory Syndrome in Infants <12 months of Age, United States, May 2020-January 2021. Pediatr Infect Dis J. 2021 Jul 1;40(7):601–5.
- 13. Holm M, Espenhain L, Glenthøj J, Schmidt LS, Nordly SB, Hartling UB, et al. Risk and Phenotype of Multisystem Inflammatory Syndrome in Vaccinated and Unvaccinated Danish Children Before and During the Omicron Wave. JAMA Pediatr. 2022 Jun 8;
- Levy N, Koppel JH, Kaplan O, Yechiam H, Shahar-Nissan K, Cohen NK, et al. Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel. JAMA. 2022 May 19;
- 15. Tian F, Yang R, Chen Z. Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials. J Med Virol. 2022 Jun 15;

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

Table 1. Characteristics of children hospitalized with acute COVID-19 and MIS-C.

Characteristic	Diagnosis			050/ 01	
	COVID-19	MIS-C	- aRD ¹ , %	95% CI	P value
Total hospitalizations, N ²	330	208			
Age (years), median $(IQR)^3$	1.9 (0.1–13.3)	8.1 (4.2–11.6)			< 0.001
Age (years), n (%)					
<1	140 (42.4)	9 (4.3)	43.4	37.7 to 49.1	< 0.001
1–4	68 (20.6)	52 (25.0)	-2.9	-10.4 to 4.6	0.45
5–11	30 (9.1)	98 (47.1)	-38.9	-46.9 to -31.0	< 0.001
12–17	92 (27.9)	49 (23.6)	-1.6	-9.6 to 6.4	0.69
Sex, n (%)					
Female	145 (43.9)	76 (36.5)	6.2	-4.9 to 17.3	0.27
Male	185 (56.1)	132 (63.5)	-6.2	-17.3 to 4.9	0.27
Comorbid conditions ⁴ , n (%)					
None/Unknown	188 (57.0)	175 (84.1)	-38.0	-45.1 to -31.0	< 0.001
≥ 1	142 (43.0)	33 (15.9)	38.0	31.0 to 45.1	< 0.001
Population group, n (%)					
White	75 (22.7)	63 (30.3)	-12.4	-22.8 to -2.0	0.02
South Asian	40 (12.1)	25 (12.0)	1.4	-6.0 to 8.7	0.71
Arab/West Asian	39 (11.8)	16 (7.7)	4.4	-2.3 to 11.1	0.20
Black	39 (11.8)	29 (13.9)	-2.2	-9.5 to 5.1	0.56
Indigenous	28 (8.5)	9 (4.3)	4.8	-0.6 to 10.3	0.08
East/Southeast Asian	18 (5.5)	12 (5.8)	3.0	-2.2 to 8.1	0.26
Latin American	5 (1.5)	18 (8.7)	-7.5	-13.3 to -1.7	0.01
Unknown	92 (27.9)	49 (23.6)			

aRD = Adjusted risk difference; CI = Confidence interval; IQR = Interquartile range; MIS-C = Multisystem inflammatory syndrome in children

¹All comparisons adjusted for age category, sex, comorbid conditions, and timing of hospitalization. Positive risk differences indicate a characteristic was more common for acute COVID-19 while negative risk differences indicate a characteristic was more common for MIS-C.

²Overall, 544 hospitalized children with SARS-CoV-2 infection were reported to the CPSP, among whom 330 children were admitted due to acute COVID-19; 493 hospitalized children were reported with suspected PIMS, among whom 208 children met the WHO definition of MIS-C.

³Continuous age was missing for four patients with acute COVID-19, though categorical age could still be determined. ⁴Comorbidities were reported as any of the following conditions: congenital heart disease, diabetes, gastrointestinal/liver disease, genetic/metabolic conditions, hematologic disorders, immunodeficiencies, malignancies, neurologic or neurodevelopmental conditions, obesity, pulmonary disease (i.e. asthma or other chronic lung disease), renal disease, rheumatologic/autoimmune disorders, tracheostomy, transplants, or other conditions.

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

Table 2. Outcomes of acute COVID-19 and MIS-C hospitalizations, overall and by age category.
--

Outcome ¹	Diagnosis		$-\mathbf{D}\mathbf{D}^2$ 0/	050/ CI	D 1
	COVID-19	MIS-C	aRD ² , %	95% CI	P value
All hospitalizations					
Supplemental oxygen	81/330 (24.6)	63/208 (30.3)	-5.6	-15.2 to 3.9	0.25
Ventilation	36/330 (10.9)	20/208 (9.6)	1.7	-4.9 to 8.2	0.62
Vasopressors	8/330 (2.4)	74/208 (35.6)	-23.1	-30.4 to -15.8	< 0.001
PICU admission	60/330 (18.2)	103/208 (49.5)	-20.3	-30.8 to -9.9	< 0.001
PICU length of stay (days)	4 (2–7)	3 (2–4)			0.04
ECMO	0/330 (0.0)	0/208 (0.0)			
Death	5/330 (1.5)	0/208 (0.0)			
Age <5 years					
Supplemental oxygen	36/208 (17.3)	10/61 (16.4)	-0.1	-13.0 to 12.6	0.98
Ventilation	18–21/208 (8.7–10.1) ³	<5/61 (<8.2)	12.8	7.0 to 18.5	< 0.001
Vasopressors	5-7/208 (2.4-3.4) ³	8/61 (13.1)	-4.7	-12.1 to 2.6	0.21
PICU admission	32/208 (15.4)	12/61 (19.7)	2.5	-8.8 to 13.8	0.66
PICU length of stay (days)	4 (2–6)	3 (1–3)			0.02
Age 5–11 years					
Supplemental oxygen	8/30 (26.7)	37/98 (37.8)	-12.9	-35.0 to 9.3	0.25
Ventilation	<5/30 (<16.7)	7–10/98 (7.1–10.2) ³	-9.8	-18.5 to -1.1	0.03
Vasopressors	0/30 (0.0)	42/98 (42.9)			
PICU admission	7/30 (23.3)	61/98 (62.2)	-34.5	-57.7 to -11.3	0.004
PICU length of stay (days)	2 (1–9)	3 (2–4)			0.68
Age 12–17 years					
Supplemental oxygen	37/92 (40.2)	16/49 (32.7)	-9.2	-27.2 to 8.9	0.32
Ventilation	11–14/92 (12.0–15.2) ³	6–9/49 (12.2–18.4) ³	-6.9	-25.1 to 11.3	0.46
Vasopressors	<5/92 (<5.4)	24/49 (49.0)	-43.5	-63.3 to -23.8	< 0.001
PICU admission	21/92 (22.8)	30/49 (61.2)	-38.1	-57.2 to -19.0	< 0.001
PICU length of stay (days)	6 (3–8)	4 (2–5)			0.11

aRD = Adjusted risk difference; CI = Confidence interval; ECMO = Extracorporeal membrane oxygenation; PICU = Pediatric intensive care unit; MIS-C = Multisystem inflammatory syndrome in children


¹Descriptive statistics are presented as frequency and proportions, or medians and interquartile ranges.

²All comparisons adjusted for sex, comorbid conditions, and timing of hospitalization. Comparisons for all hospitalizations also adjust for age category. Positive risk differences indicate an outcome was more common for acute COVID-19 while negative risk differences indicate an outcome was more common for MIS-C.

³Frequencies and percentages are reported using ranges to prevent back-calculation of frequencies <5.

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA





Appendix Figure 1. Time series of acute COVID-19 hospitalizations (<18 years), MIS-C hospitalizations (<18 years), and SARS-CoV-2 infections (all ages) across Canada from January 2020–May 2021.

Data for COVID-19 and MIS-C hospitalizations represent the three-week moving average of cases included in this study. SARS-CoV-2 infections were ascertained from the Public Health Agency of Canada, available at https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html, and reflect the date of illness onset.

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

CPSP COVID-19 Study Team (listed alphabetically)

Author name	Affilitation(s)
Krista Baerg, MD	Department of Pediatrics, University of Saskatchewan, Saskatoon, Canada
	Division of General Pediatrics, Jim Pattison Children's Hospital, Saskatchewan Health Authority, Saskatoon, Canada
Guillaume Beaudoin-Bussières, BSc	Centre de Recherche du CHUM et Département de Microbiologie, Infectiologie
	et Immunologie, Université de Montréal, Montreal, Canada
Camille Beaufils, MD	Division of Paediatric Rheumatology-Immunology, CHU Sainte-Justine,
	Department of Pediatrics, University of Montreal, Montreal, Canada
Terri-Lyn Bennett, MSc	Public Health Agency of Canada, Ottawa, Canada
Susanne M. Benseler, MD	Alberta Children's Hospital Research Institute, Cumming School of Medicine,
	University of Calgary, Calgary, Canada
	Division of Rheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Canada
Roberta A. Berard, MD	Division of Rheumatology, Department of Pediatrics, Children's Hospital at
	London Health Sciences Centre, London, Canada
Kevin Chan, MD	Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
	Department of Children's and Women's Health, Trillium Health Partners,
	Mississauga, Canada
	Institute for Better Health, Trillium Health Partners, Mississauga, Canada
Claude Cyr, MD	Service de Soins Intensifs Pédiatriques, Centre Hospitalier Universitaire de
	Sherbrooke, Sherbrooke, Canada
Nagib Dahdah, MD	Division of Pediatric Cardiology, CHU Sainte-Justine, Department of Pediatrics,
	University of Montreal, Montreal, Canada
Elizabeth J. Donner, MD	Division of Neurology, The Hospital for Sick Children, Toronto, Canada
	Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto,
	Toronto, Canada
Olivier Drouin, MDCM	Division of General Pediatrics, Department of Pediatrics, CHU Sainte-Justine,
	Montreal, Canada
	Department of Social and Preventive Medicine, School of Public Health,
	Université de Montréal, Montréal, Canada
Tala El Tal, MD	Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Canada
Joanne E. Embree, MD	Department of Paediatrics and Child Health, University of Manitoba, Winnipeg, Canada
	Department of Medical Microbiology and Infectious Diseases, University of
	Manitoba, Winnipeg, Canada
Daniel S. Farrar, MPH	Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada
Catherine Farrell, MD	Division of Paediatric Intensive Care, Department of Pediatrics, CHU Sainte-
	Justine, Montréal, Canada
Andrés Finzi, PhD	Centre de Recherche du CHUM et Département de Microbiologie, Infectiologie
	et Immunologie, Université de Montréal, Montreal, Canada
Sarah Forgie, MD	Division of Infectious Diseases, Department of Pediatrics, University of Alberta,
	Edmonton, Canada
	Stollery Children's Hospital, Edmonton, Canada
Ryan Giroux, MD	Women's and Children's Health Program, St. Michael's Hospital, Unity Health Toronto, Toronto, Canada
Elie Haddad, MD	Division of Paediatric Rheumatology-Immunology, CHU Sainte-Justine,
	Department of Pediatrics, University of Montreal, Montreal, Canada
Fatima Kakkar, MD	Division of Infectious Diseases, CHU Sainte-Justine, Montreal, Canada
Kristopher T. Kang, MD	Department of Pediatrics, University of British Columbia, Vancouver, Canada
Melanie King, BA	Canadian Paediatric Surveillance Program, Canadian Paediatric Society, Ottawa,
-	Canada

COVID-19 AND MIS-C HOSPITALIZATIONS IN CANADA

Melanie Laffin, BCom	Canadian Paediatric Surveillance Program, Canadian Paediatric Society, Ottawa, Canada
Bianca Lang, MD	Division of Rheumatology, Department of Pediatrics, Dalhousie University, Halifax, Canada
Ronald M. Laxer, MDCM	Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada
	Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
Brian W. McCrindle, MD	The Labatt Family Heart Centre, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Ont., Canada
Charlotte Moore Hepburn, MD	Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Canada Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
Marie-Paule Morin, MD	Division of Paediatric Rheumatology-Immunology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Canada
Shaun K. Morris, MD	Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Canada
	Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
	Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada
	Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
Julia Orkin, MD	Division of Paediatric Medicine, The Hospital for Sick Children, Toronto, Canada
	Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada
Jesse Papenburg, MD	Division of Pediatric Infectious Diseases, Department of Pediatrics, Montreal
	Children's Hospital, Montréal, Canada
	Division of Microbiology, Department of Clinical Laboratory Medicine, McGill University Health Centre, Montréal, Canada
Catherine M. Pound, MD	Division of Consulting Pediatrics, Department of Pediatrics, Children's Hospital
Catherine Wi. I Guild, MD	of Eastern Ontario, Ottawa, Canada
Victoria E. Price, MBChB	Division of Paediatric Hematology/Oncology, Department of Pediatrics,
	Dalhousie University, Halifax, Canada
Jean-Phillippe Proulx-Gauthier, MD	Division of Pediatric Rheumatology, Department of Pediatrics, CHU de Québec- Université Laval, Québec City, Canada
Rupeena Purewal, MD	Department of Pediatrics, University of Saskatchewan, Saskatoon, Canada
	Division of Paediatric Infectious Diseases, Jim Pattison Children's Hospital, Saskatchewan Health Authority, Saskatoon, Canada
Manish Sadarangani, BM BCh	Department of Pediatrics, University of British Columbia, Vancouver, Canada
	Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, Canada
Marina l. Salvadori, MD	Public Health Agency of Canada, Ottawa, Canada
Rosie Scuccimarri, MD	Division of Paediatric Rheumatology, Montreal Children's Hospital and McGill University Health Centre, Montreal, Canada
Roseline Thibeault, MD	Division of Infectious Diseases, Department of Pediatrics, CHU de Québec- Université Laval, Québec City, Canada
Karina A. Top, MD	Department of Pediatrics, Dalhousie University, Halifax, Canada
Isabelle Viel-Thériault, MD	Division of Infectious Diseases, Department of Pediatrics, CHU de Québec- Université Laval, Québec City, Canada
Rae S. M. Yeung, MD	Division of Rheumatology, Department of Pediatrics, The Hospital for Sick
	Children, University of Toronto, Canada
	Cell Biology Program, The Hospital for Sick Children, Toronto, Canada
	Department of Immunology and Institute of Medical Science, University of Toronto, Toronto, Canada